Howard G. Welgus, a director at Arcutis Biotherapeutics (ARQT), sold 10,000 shares on April 1, 2026, as reported in a recent SEC Form 4 filing. This transaction, executed at a price of $23.88 per share, aligns with Welgus’s typical monthly trading patterns, matching previous sales that ranged from 9,208 to 10,139 shares. Notably, this sale represented 20% of his direct holdings, leaving him with 39,744 shares, a significant reduction from his holdings two years ago.
This sale is framed as a pre-planned liquidity event under a 10b5-1 plan, rather than a signal of diminished confidence in the company. Arcutis has seen its stock rise approximately 65% over the past year, buoyed by robust revenue growth driven by its eczema treatment, ZORYVE. The company reported $372.1 million in net product revenue for 2025, reflecting a 123% year-over-year increase, and is poised for continued commercial momentum.
For investors, the key takeaway is that the insider sale appears to be a routine transaction rather than a bearish signal, with the company’s strong financial performance and upcoming regulatory submissions indicating a positive trajectory for Arcutis.
Source: fool.com